Stability Indicating High-Performance Liquid Chromatography Method for the Estimation of Artemether in Capsule Dosage Forms

Shrivastava A, Issarani R¹, Nagori BP¹

Department of Pharm. Sciences, B.R. Nahata College of Pharmacy, Mhow-Neemuch Road, Mandsaur (M.P) - 458 001, ¹L.M. College of Science and Technology, Pharmacy wing, Shastri Nagar, Sector A, Jodhpur (Rajasthan), India

Address for correspondence: Mr. Alankar Shrivastava; E-mail: alankarshrivastava@gmail.com

ABSTRACT

A new simple, sensitive, precise, and accurate high-performance liquid chromatography (HPLC) method of analysis for artemether both as a bulk drug and in capsule formulations was developed and validated. The method employed mobile phase acetonitrile (ACN) and buffer in the ratio 65:35 of pH 6.5 adjusted with tryethylamine. The linear regression analysis data for the calibration plots showed good linear relationship with \( r^2 = 0.9996 \) in the concentration range 250-750 \( \mu \)g/ml. The mean value slope and intercept were 9355.5 and –93.5, respectively. The method was validated for precision, accuracy, and recovery studies. Limit of detection (LOD) and Limit of quantitation (LOQ) for artemether were found to be 21.83-750 \( \mu \)g/ml, respectively. The method has been successfully applied in the analysis of marketed capsule formulations. The presented method was found to be reliable to separate all the degradents from all the stress conditions with resolution of more than 1.5 showing that it is a stability indicating method.

Key words: ART, forced degradation, high-performance liquid chromatography, stability indicating method of artemether

DOI: 10.4103/0975-1483.62220

INTRODUCTION

Artemether ((3R, 5aS, 6R, 8aS, 9R, 10S, 12R, 12aR)-decahydro-10-methoxy-3, 6, 9-trimethyl-3, 12-epoxy-12Hpyrano [4,3-j]-1, 2-benzodioxepin) is a semisynthetic polyoxygenated amorphene-containing aperoxide bridge that confers potent antimalarial activity.⁴ It is the O-methyl ether prodrug of dihydroartemisinin and a derivative of artemisinin (qinghaosu), the principal antimalarial constituent of the Chinese herb Artemisia annua (qing hao).⁵ Artemether is active against the erythrocytic stage of multidrug-resistant strains of Plasmodium falciparum. The antimalarial activity has been attributed to chemical activation of the drug within the food vacuole of the intraerythrocytic stage of the parasite; it is proposed that reductive cleavage of the aperoxide bridge by heme liberated during digestion of hemoglobin generates free radicals, which induce oxidative stress and alkylate heme and vital parasite proteins.⁶ An interaction with membrane phospholipids has also been suggested.⁷ The peroxide group in these compounds appears essential for activity and the peroxide group is retained in the active metabolite, dihydroartemisinin.⁸

Because of the promising activity exhibited by artemether against multidrug-resistant strains of P. falciparum, several researchers have focused on the development of various analytical methods to determine artemether in different matrices, such as plant extracts, serum, and pharmaceutical formulations. These methods include gas UV spectrophotometry,⁹ high-performance liquid
chromatography (HPLC) based on UV absorption,[7-9] chromatography-mass spectrometry (GC-MS),[10] chemiluminescence and electrochemical detection,[11] high-performance thin-layer chromatography (HPTLC),[12,13] and the capillary electrophoresis techniques.[14] However, to the best of our knowledge no stability indicating HPLC method has been published in the available literature.

The aim of the present work is to develop and validate[15] an accurate, specific, and precise stability indicating HPLC method for determination of artemether as bulk drug and in solid dosage forms.

**MATERIALS AND METHODS**

HPLC Apparatus (shimadzu) equipped with LC-10 ATvp, double reciprocating plunger pump and SPD-10 Avp UV detector, and deuterium lamp as a light source ranging 190-600 nm was used. Hypersil Octadecyl silane (ODS) column, (250 × 4) mm, 5 μm particle size of packing, pore size 120 Å, Thermo Electron Corporation. Marketed formulations Larither and Falcidol capsules were purchased from a local market. Mobile phase selected was ACN and buffer in the ratio of 65:35 of pH 6.5 adjusted with triethylamine. Wavelength selected was 210 nm. Standards and facilities were provided by Oasis Lab, Ahmedabad.

**Preparation of a mobile phase**

650 volumes of acetonitrile (ACN) was mixed with 0.005 M potassium dihydrogen phosphate (KH₂PO₄), adjusted to pH 6.5 with triethylamine filtered and degassed.

**Preparation of 0.005 M KH₂PO₄**

0.340 g KH₂PO₄ was transferred to a 500 ml volumetric flask and dissolved up to the mark with double distilled water.

**Calibration curve**

Suitable aliquots of the standard stock solution (10 mg/ml) of ART (0.25, 0.35, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65 and 0.75) were taken in 10 ml volumetric flasks and diluted with a mobile phase up to the mark to get 250, 350, 400, 450, 500, 550, 600, 650, and 750 mg/ml solution of drug. The prepared solutions were then filtered through 0.45 μ filter, and 20 μl of each solution was injected.

The calibration data, the linear regression equation, and correlation coefficient for artemether were found to be $y = 9355.5x - 93.7$ and $r = 0.9998$, where $y$ is response and $x$ is the concentration of drug solution, respectively.

**VALIDATION OF PROPOSED METHOD**

**Linearity**

Linearity was assessed by two methods.

**Visual examination**

The numbers of points equally distributed on both sides of best fit line were inspected. From the calibration curve it is clearly seen that out of 9 points, 4 are on positive side (upper side of best fit line), 4 are on negative side (lower side of best fit line) and 1 is on the best fit line.

**Residual analysis**

Residuals were calculated and a graph was plotted between the residuals/deviations (predicted response-experimental response) and concentration. Distribution of residuals between upper and lower side of the regression line shows linearity.

**Range**

**Working range**

It begins from limit of quantification to the maximum concentration used for the development of the analytical method. In this case it is equal to 21.8317-750 μg/ml.

**Linearity range**

It is the interval in which the response is directly proportional to the concentration between the upper and lower levels (which is generally ±5% of the intercept of average value). In this case it is equal to 250-750 μg/ml.

**Target concentration**

It is defined as the concentration which is equal to the midpoint of linearity range [(250 + 750)/2] = 500 μg/ml.

**Target range**

It is that concentration which is 80%, 100% and 120% of the target concentration. In this case these are equal to 400, 500, and 600 μg/ml.

**Precision**

**Repeatability**

Assessed by the area of six replicate determinations of ART solution at 100% of the target concentration, i.e. at 500 μg/ml. RSD obtained because of variation in area was 0.257 showing that the method it repeatable.

**Intrday and Interday**

Method was repeated at three concentration levels, i.e. 80%, 100%, and 120% for three times in a day for intraday and in
Stability indicating high-performance liquid chromatography method of artemether

three consecutive days for interday precision. RSD values obtained were 0.643 and 0.712 for intraday and interday, respectively.

Accuracy

5 ml of a preanalyzed capsule powder solution (500 µg/ml) and 0.1, 0.2 and 0.3 ml of an ART standard solution (1 mg/ml) were mixed within three different 10 ml volumetric flask, respectively. The estimation of drug was done by a proposed method. The results of recovery of Larither and Falcidol capsules are shown in Tables 1 and 2, respectively.

System suitability

Five injections of the same solution (500 µg/ml) were injected and variations between area and RT were observed. RSD due to changes in area and RT were found to be 0.274 and 0.326, respectively. Asymmetric and tailing factors were 1.20 and 1.30, respectively. The number of theoretical plates for the test concentration was 6998.

Limit of detection and limit of quantitation

The value of limit of detection (LOD) and limit of quantitation (LOQ) were calculated from the formula $3.3 \times (SD/S)$ and $10 \times (SD/S)$, respectively, by using mean SD of data from the calibration curve. In this proposed method, 7.204 and 21.8317 µg/ml of ART are calculated as LOD and LOQ, respectively.

Estimation of artemether in a capsule dosage form

50 mg equivalent powder of a capsule dosage form was transferred to four different 50 ml volumetric flasks. 65 ml of ACN was added and sonicated for 15 min. The flasks were then diluted up to a volume with 0.005 M phosphate buffer, filtered with 0.45 µm filter, and 20 µl was injected.

A standard artemether solution was prepared by dissolving 100 mg of drug in a 10 ml volumetric flask and diluting up to the volume. 0.5 ml of this solution was transferred to a 10 ml volumetric flask. Results of estimation of drug in two different capsule formulation are given in Table 3.

### Table 1: Results of recovery of larither capsules

| Conc. (µg/ml) | Conc. found before spiking (µg/ml) (C₁) | Conc. of std added (µg/ml) (C₂) | Conc. found after spiking (µg/ml) (C₃) | %Recovery (C₃ - C₁)/C₁ × 100/C₂ | Mean ± S.D | RSD |
|---------------|----------------------------------------|---------------------------------|----------------------------------------|---------------------------------|-------------|-----|
| 250           | 247.558                                | 100                             | 345.89                                 | 99.52                           | 99.37 ± 0.76 | 0.765 |
| 250           | 247.558                                | 200                             | 344.82                                 | 99.91                           | 99.28 ± 0.514 | 0.517 |
| 250           | 247.558                                | 300                             | 446.15                                 | 99.68                           | 99.32 ± 0.3132 | 0.3132 |

### Table 2: Result of recovery study of falcidol caps

| Conc. (µg/ml) | Conc. found before spiking (µg/ml) (C₁) | Conc. of std added (µg/ml) (C₂) | Conc. found after spiking (µg/ml) (C₃) | %Recovery (C₃ - C₁)/C₁ × 100/C₂ | Mean ± S.D | RSD |
|---------------|----------------------------------------|---------------------------------|----------------------------------------|---------------------------------|-------------|-----|
| 250           | 244.75                                 | 100                             | 340.95                                 | 98.89                           | 99.34 ± 0.514 | 0.517 |
| 250           | 244.75                                 | 200                             | 437.68                                 | 98.41                           | 99.66 ± 0.32946 | 0.32946 |
| 250           | 244.75                                 | 300                             | 545.11                                 | 100.06                          | 99.62 ± 0.315 | 0.315 |

### Table 3: Estimation of artemether in capsule dosage form

| Brand name | Label claim (mg) | Conc. found (mg) | Mean ± SD | %Drug found | Mean% ± SD | %RSD |
|------------|------------------|------------------|-----------|-------------|------------|------|
| A          | 40               | 39.678           | 39.734 ± 0.1304 | 99.33       | 99.37 ± 0.31324 | 0.315 |
|            |                  | 39.904           |           | 99.76       |            |
|            |                  | 39.598           |           | 98.99       |            |
|            |                  | 39.756           |           | 99.39       |            |
|            |                  | 39.444           |           | 98.61       |            |
|            |                  | 39.542           |           | 98.85       |            |
|            |                  | 39.323           |           | 98.31       |            |
|            |                  | 39.243           |           | 98.11       |            |

| B          | 40               | 39.388 ± 0.13179 | 98.47 ± 0.32946 | 0.334 |
|            |                  | 39.85            |            |
|            |                  | 98.31            |            |
|            |                  | 98.11            |            |

Brand A - Larither caps; Brand B - Falcidol caps
The calculation was done by using the formula:

\[
\text{Ar temether content (mg)} = \frac{(\text{Area test}/\text{Area std}) \times (100/10) \times (0.5/10) \times (50/\text{wt capsule powder}) \times (\text{potency of std}/100) \times (\text{average wt powder/cap})}{300}
\]

**Forced degradation studies**

**Acid hydrolysis**

0.5 ml of a standard stock solution (10 mg/ml) was transferred to a 10 ml volumetric flask and in this 1 ml of 0.01 N HCl, volume was made to about 5 ml with mobile phase and heated on the water bath at 60°C for 6 hours. Flask was then cooled to room temperature and diluted up to mark with mobile phase. Solution was then filtered through 0.45 μm filter and 20 μl solution was injected [Figure 1].

**Alkaline hydrolysis**

0.5 ml of standard stock solution (10 mg/ml) was transferred to 10 ml volumetric flask and in this 1 ml of 0.001 N NaOH, volume was made to about 5 ml with mobile phase and heated on the water bath at 60°C for 6 hours. Flask was then cooled to room temperature and diluted up to mark with mobile phase. Solution was then filtered through 0.45 μm filter, and 20 μl solution was injected [Figure 1].

**Oxidation**

0.5 ml of the stock solution (10 mg/ml) was taken in a 10 ml volumetric flask and 1 ml of 3% H₂O₂ was then added. The solution was then kept at room temperature for 18 h. The solution was then filtered through 0.45 μm filter, and 20 μl solution was injected [Figure 2].

**Thermal degradation**

**Dry heat**

100 mg drug was taken in a 10 ml volumetric flask and heated in the oven at 60°C for 24 h, diluted up to the mark with the mobile phase. The solution was then filtered through 0.45 μm filter, and 20 μl solution was injected [Figure 4].
Stability indicating high-performance liquid chromatography method of artemether

Table 4: Summary of results of forced degradation studies

| Sample exposure condition | No. of degradation products (RT) | Figure no. | %Degradation (±SD) | S.E.M | %Recovery |
|---------------------------|---------------------------------|------------|--------------------|-------|-----------|
| Acid hydrolysis           | 5 (3.16, 3.42, 3.68, 3.89, 7.18) | 1. a       | 22.312 (±4.3)      | 0.91  | 77.69     |
| Alkaline hydrolysis       | 5 (2.0, 2.21, 3.39, 3.69, 4.43) | 1. b       | 15.747 (±3.8)      | 1.6   | 84.25     |
| Oxidation                 | 3 (2.04, 3.69, 5.10)            | 1. c       | 13.622 (±4.2)      | 0.88  | 86.38     |
| Heat Dry                  | 5 (2.02, 2.26, 3.41, 3.93, 4.91) | 1. d       | 11.444 (±3.6)      | 1.2   | 88.56     |
| Wet                       | 7 (3.66, 3.87, 4.40, 4.83, 5.75, 6.13, 7.01) | 1. e       | 12.813 (±5.4)      | 2.4   | 87.18     |

Table 5: Summary of validation parameters

| Linearity                  | 250-750 (µg/ml); r = 0.9998 |
|----------------------------|-----------------------------|
| Range (µg/ml)              | 250-750                     |
| Linear range               | 21,831-750                  |
| Target range               | 400, 500 and 600            |
| Target concentration       | 500                         |
| Precision (%RSD)           | 0.256                       |
| Repeatability              | 0.642                       |
| Interday                   | 0.712                       |
| Accuracy (%recovery)       | 99.36                       |
| LOD (µg/ml)                | 7.20445                     |
| LOQ (µg/ml)                | 21.8317                     |

Wet heat

0.5 ml of the standard stock solution (10 mg/ml) of drug was transferred to a 10 ml volumetric flask and diluted with about 5 ml of the mobile phase and kept on water bath at 100°C for 4 h. The solution was then filtered through 0.45 µm filter, and 20 µl solution was injected [Figure 5].

UV treatment

0.5 ml of the standard stock solution (10 mg/ml) was transferred to a 10 ml volumetric flask, diluted to the mark, and kept in UV chamber overnight for 24 h. The solution was then filtered through 0.45 µm filter, and 20 µl solution was injected, no degradation was observed.

CONCLUSION

The developed HPLC technique is precise, accurate, specific, and stability indicating. Statistical analysis proves that the method is repeatable and selective for the analysis of artemether as bulk drug and in pharmaceutical formulations. The summary of results of stability studies and validation parameters of method are presented in Tables 4 and 5 respectively. The method can be used to determine the purity of the drug available from various sources by detecting the related impurities. It may be extended to study the degradation kinetics of artemether and for its estimation in plasma and other body fluids. As the method separates the drug from potential degradation products in different storage conditions with the resolution of more than 1.5, it is stability indicating.

REFERENCES

1. Meshnick SR, Taylor TE, Kamchongwongpaisan S. Artemisinin and the antimalarial endoperoxides: From herbal remedy to targeted chemotherapy. Microbiol Rev 1996;60:301-15.
2. Klayman DL. Qinhuou (Artemisinin): An antimalerial drug from China. Science n. 1985;228:1049-55.
3. Cumming JN, Ploypradath P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: Mechanism(s) of action. Adv Pharmacol 1997;37:253-97.
4. Basco LK, Le Bras J. In vitro Activity of Artemisinin Derivatives Against African Isolates and Clones of Plasmodium falciparum. Am J Trop Med Hyg 1993;49:301-7.
5. Shrivastava A, Nagori BP, Saini P, Issarani R and Gaur SS. New Simple and Economical Spectrophotometric Method for Estimation of Artemether in Pharmaceutical Dosage Forms. Asian J. Research Chem 2008;1(1):19-21.
6. Monographs for antimalarial drug. International Pharmacopoeia. 187-196. Available from: http://whqlibdoc.who.int/publications/2003/9241545364_part4.pdf. As assessed on 19/07/07.
7. Thomas CG, Ward SA, Edwards G. Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high-performance liquid chromatography with ultraviolet detection. J Chromatogr 1992;583:131-6.
8. Chimanuka B, Gabriëls M, Detaevernier MR, Plaizier-Vercammen JA. Preparation of β-artemether liposomes, their HPLC-UV evaluation and relevance for clearing recrudescent parasitaemia in Plasmodium chabaudi malaria-infected mice. J Pharm Biomed Anal 2002;28:13-22.
9. Muhia DK, Mberu EK, Watkins WM. Differential extraction of artemether and its metabolite dihydroartemisinin from plasma and determination by high-performance liquid chromatography. J Chromatogr B 1994;660:196-9.
10. Mohamed SS, Khalid SA, Ward SA, Wan TS, Tang HP, Zheng M, et al. Simultaneous determination of artemether and its major metabolite dihydroartemisinin in plasma by gas chromatography-mass spectrometry-selected ion monitoring. J Chromatogr B Biomed Sci Appl
11. Karbwang J, Na-Bangchang K, Molunto P, Banmairuroi V, Congpuong K, Determination of artemether and its major metabolite, dihydroartemisinin, in plasma using high-performance liquid chromatography with electrochemical detection. J Chromatogr B 1997;690:259-65.

12. Tayade NG, Nagarsenker MS. Validated HPTLC method of analysis for artemether and its formulations. J Pharm Biomed Anal 2007;43:839-44.

13. Gabriëls M, Plaizier-Vercammen JA. Densitometric thin-layer chromatographic determination of artemisinin and its lipophilic derivatives, artemether and arteether. J Chromatogr Sci 2003;41:359-66.

14. Avery BA, Venkatesh KK, Avery MA. Rapid determination of artemisinin and related analogues using high-performance liquid chromatography and an evaporative light scattering detector. J Chromatogr B Biomed Sci Appi 1999;730:71-80.

15. ICH Q2B Guideline: Validation of Analytical Procedures Methodology. Link: Available from: http://www.ikev.org/haber/stabilite/kitap/36%201.8%2020%20Stability%20Workshop%20ICH%20Q2B%20C%20pdf. As assessed on 14/04/07.

Source of Support: Nil, Conflict of Interest: None declared.